Whereas previous studies have shown that TAMs were recruited by cancer cells after paclitaxel treatment and blocked the CD8+ T cell-dependent chemotherapy response [129], paclitaxel was newly identified as an agonist of TLR4 on TAMs and directly polarized this anti-inflammation population into a pro-inflammatory phenotype [59, 60]. The gene discussed is CD8A; the disease is cancer.